Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.

Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...

Florida's legendary rockabilly outfit Rocket 88 returns to Tropical Heatwave 2025, bringing their cosmic-themed, high-energy performance to the Cuban Club Ballroom. With endorsements from Jerry Lee ...

Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...

SpaceX has released footage of the most recent Starship launch from an angle I didn't think was possible, showcasing the ...

On March 6, dozens of videos of the fiery skies over Marathon spread like wildfire on social media when a test flight of ...

Lockheed Martin expects its mid-size demonstration satellite will launch on Saturday on a Firefly Aerospace Alpha rocket.

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...